Elastrin Therapeutics is a US and UK based biotech startup developing novel therapies to reverse chronic cardiovascular and lung diseases. Its underlying technology was developed by Prof. Vyavahare during the last 20 years at Clemson University. The team consists of seven experts and has built a proprietary platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded. This is achieved via targeting drug-loaded nanoparticles directly to the diseased tissue using the companies’ proprietary antibody. Elastrin’s lead product will be tested in clinical trials starting in 2024 and become commercially available in 2027.